Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After=2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study

被引：0

作者：

Schuster, Stephen J. ^{[1
]}

Sehn, Laurie H. ^{[2
]}

Bartlett, Nancy L. ^{[3
]}

Matasar, Matthew ^{[4
]}

Assouline, Sarit ^{[5
]}

Giri, Pratyush ^{[6
]}

Kuruvilla, John ^{[7
]}

Shadman, Mazyar ^{[8
,9
]}

Cheah, Chan Y. ^{[10
,11
]}

Dietrich, Sascha ^{[12
]}

Fay, Keith ^{[13
,14
]}

Ku, Matthew ^{[15
]}

Nastoupil, Loretta ^{[16
]}

Wei, Michael C. ^{[17
]}

Yin, Shen ^{[17
]}

To, Iris ^{[17
]}

Huang, Jiangeng ^{[17
]}

Kwan, Antonia ^{[17
]}

Penuel, Elicia ^{[17
]}

Budde, L. Elizabeth ^{[18
]}

机构：

[1] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[2] Univ British Columbia, BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[4] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[5] Jewish Gen Hosp, Montreal, PQ, Canada

[6] Royal Adelaide Hosp, Adelaide, Australia

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[9] Univ Washington, Seattle, WA USA

[10] Sir Charles Gairdner Hosp, Linear Clin Res, Nedlands, Australia

[11] Univ Western Australia, Perth, Australia

[12] Heidelberg Univ, Heidelberg, Germany

[13] St Vincents Hosp, Sydney, Australia

[14] Royal North Shore Hosp, Sydney, Australia

[15] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[17] Genentech Inc, South San Francisco, CA USA

[18] City Hope Natl Med Ctr, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

IBCL; non-Hodgkin lymphoma; indolent lymphoma; follicular lymphoma; bispecific antibody;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-335

引用

页码：S497 / S497

页数：1

共 50 条

[41] Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Coiffier, Bertrand
Pro, Barbara
Prince, H. Miles
Foss, Francine
Sokol, Lubomir
Greenwood, Matthew
Caballero, Dolores
Borchmann, Peter
Morschhauser, Franck
Wilhelm, Martin
Pinter-Brown, Lauren
Padmanabhan, Swaminathan
Shustov, Andrei
Nichols, Jean
Carroll, Susan
Balser, John
Balser, Barbara
Horwitz, Steven
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : 631 - 636
[42] Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 15 - 15
[43] Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
Jain, Preetesh
Romaguera, Jorge
Srour, Samer A.
Lee, Hun J.
Hagemeister, Frederick
Westin, Jason
Fayad, Luis
Samaniego, Felipe
Badillo, Maria
Zhang, Liang
Nastoupil, Lorreta
Kanagal-Shamanna, Rashmi
Fowler, Nathan
Wang, Michael L.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (03) : 404 - 411
[44] Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with=2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study
Hutchings, Martin
Avigdor, Abraham
Sureda Balari, Anna Maria
Jose Terol, Maria
Bosch, Francesc
Corradini, Paolo
Larsen, Thomas S.
Rueda Dominguez, Antonio
Skarbnik, Alan
Joergensen, Judit Meszaros
Lavie, David
Gurion, Ronit
Zinzani, Pier Luigi
Pinto, Antonio
Cordoba, Raul
Bottos, Alessia
Li, Donghang
Relf, James
De L'Etang, Audrey Filezac
Sellam, Gila
Gritti, Giuseppe
BLOOD, 2023, 142
[45] CD3xCD20 Bispecific Antibodies Yields Long-Term Survival in Relapsed/Refractory B Cell Lymphoma: A Follow-up Study of Patients Treated in Pivotal Phase 1/2 Trials
Kyvsgaard, Emil Ramso
Clausen, Michael Roost
Riley, Anna Caroline Hasselbalch
Niemann, Carsten Utoft
Gronbaek, Kirsten
Hutchings, Martin
Husby, Simon
BLOOD, 2023, 142
[46] A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)
Ghione, Paola
Palomba, Maria Lia
Ray, Markqayne D.
Limbrick-Oldfield, Eve H.
Owen, Jess
Kanters, Steve
Bobillo, Sabela
Ribeiro, Maria Teresa
Jacobson, Caron A.
Neelapu, Sattva S.
Ghesquieres, Herve
Nahas, Myrna
Beygi, Sara
Patel, Anik R.
Gribben, John G.
BLOOD, 2022, 140 : 4676 - 4677
[47] A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis
Kato, Koji
Fujii, Nobuharu
Makita, Shinichi
Goto, Hideki
Kanda, Junya
Shimada, Kazuyuki
Akashi, Koichi
Izutsu, Koji
Teshima, Takanori
Fukuda, Natsuko
Sumitani, Tokuhito
Nakamura, Shota
Sumi, Hiroyuki
Shimizu, Shinji
Kakurai, Yasuyuki
Yoshikawa, Kenji
Tobinai, Kensei
Usui, Noriko
Hatake, Kiyohiko
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (03) : 409 - 420
[48] A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis
Koji Kato
Nobuharu Fujii
Shinichi Makita
Hideki Goto
Junya Kanda
Kazuyuki Shimada
Koichi Akashi
Koji Izutsu
Takanori Teshima
Natsuko Fukuda
Tokuhito Sumitani
Shota Nakamura
Hiroyuki Sumi
Shinji Shimizu
Yasuyuki Kakurai
Kenji Yoshikawa
Kensei Tobinai
Noriko Usui
Kiyohiko Hatake
International Journal of Hematology, 2023, 117 : 409 - 420
[49] Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.
Borbath, Ivan
Van Laethem, Jean-Luc
Karwal, Mark
Verslype, Chris
Van Vlierberghe, Hans
Kardosh, Adel
Bergamo, Francesca
Stal, Per
Sarker, Debashis
Palmer, Daniel H.
Edeline, Julien
Cattan, Stephane
Kudo, Masatoshi
Cheng, Ann-Lii
Ogasawara, Sadahisa
Siegel, Abby B.
Hatogai, Ken
Wang, Anran
Vogel, Arndt
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up
Reiter, Andreas
Gotlib, Jason
Radia, Deepti H.
Alvarez-Twose, Ivan
Deininger, Michael W.
George, Tracy I.
Panse, Jens
Pettit, Kristen M.
Vannucchi, Alessandro M.
Platzbecker, Uwe
Hermine, Olivier
Elshoury, Amro
Livideanu, Christina Bulai
Mesa, Ruben
Ustun, Celalettin
Triggiani, Massimo
Dybedal, Ingunn
Jurcic, Joseph
Zanotti, Roberta
Span, Lambert F.
Oh, Stephen T.
Yacoub, Abdulraheem
Hexner, Elizabeth O.
Bose, Prithviraj
Lee, Stephanie
Sperr, Wolfgang R.
Griffiths, Elizabeth A.
Butler, Matthew
Bidollari, Ilda
Lin, Hui-Min
Rylova, Svetlana
Munoz-Gonzalez, Javier I.
DeAngelo, Daniel J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S425 - S426

← 1 2 3 4 5 →